###begin article-title 0
Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer
###end article-title 0
###begin p 1
###xml 158 163 <span type="species:ncbi:9606">human</span>
###xml 235 240 <span type="species:ncbi:9606">human</span>
The expression of GnRH (GnRH-I, LHRH) and its receptor as a part of an autocrine regulatory system of cell proliferation has been demonstrated in a number of human malignant tumors, including cancers of the ovary. The proliferation of human ovarian cancer cell lines is time- and dose-dependently reduced by GnRH and its superagonistic analogs. The classical GnRH receptor signal-transduction mechanisms, known to operate in the pituitary, are not involved in the mediation of antiproliferative effects of GnRH analogs in these cancer cells. The GnRH receptor rather interacts with the mitogenic signal transduction of growth-factor receptors and related oncogene products associated with tyrosine kinase activity via activation of a phosphotyrosine phosphatase resulting in downregulation of cancer cell proliferation. In addition GnRH activates nucleus factor kappaB (NFkappaB) and protects the cancer cells from apoptosis. Furthermore GnRH induces activation of the c-Jun N-terminal kinase/activator protein-1 (JNK/AP-1) pathway independent of the known AP-1 activators, protein kinase (PKC) or mitogen activated protein kinase (MAPK/ERK).
###end p 1
###begin p 2
###xml 27 32 <span type="species:ncbi:9606">human</span>
Recently it was shown that human ovarian cancer cells express a putative second GnRH receptor specific for GnRH type II (GnRH-II). The proliferation of these cells is dose- and time-dependently reduced by GnRH-II in a greater extent than by GnRH-I (GnRH, LHRH) superagonists. In previous studies we have demonstrated that in ovarian cancer cell lines except for the EFO-27 cell line GnRH-I antagonist Cetrorelix has comparable antiproliferative effects as GnRH-I agonists indicating that the dichotomy of GnRH-I agonists and antagonists might not apply to the GnRH-I system in cancer cells. After GnRH-I receptor knock down the antiproliferative effects of GnRH-I agonist Triptorelin were abrogated while the effects of GnRH-I antagonist Cetrorelix and GnRH-II were still existing. In addition, in the ovarian cancer cell line EFO-27 GnRH-I receptor but not putative GnRH-II receptor expression was found. These data suggest that in ovarian cancer cells the antiproliferative effects of GnRH-I antagonist Cetrorelix and GnRH-II are not mediated through the GnRH-I receptor.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 924 925 924 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 926 927 926 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 819 824 <span type="species:ncbi:9606">human</span>
The hypothalamic decapeptide gonadotropin releasing hormone (GnRH, GnRH-I), also called luteinizing hormone releasing hormone (LHRH), plays a key role in the regulation of mammalian reproduction [1-3]. It is released from the hypothalamus in a pulsatile manner and stimulates the synthesis and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In addition to this classic hypophysiotropic actions, GnRH functions as a modulator of the activity of diverse systems in the brain and many peripheral organs [for review see [4]]. An autocrine/paracrine function of GnRH has been suggested to exist, for instance, in the placenta, granulosa cells, myometrium, and lymphoid cells [for review see [4,5]]. In addition, it is probable that such GnRH-I-based autocrine systems are present in a number of human malignant tumors including cancers of the ovary, endometrium, breast and prostate [for review see [4,5]].
###end p 4
###begin title 5
###xml 21 26 <span type="species:ncbi:9606">human</span>
The GnRH-I system in human ovarian cancers
###end title 5
###begin p 6
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 197 202 <span type="species:ncbi:9606">human</span>
In earlier studies the expression of GnRH-I and its receptor (GnRH-I receptor) as well as direct antiproliferative effects of GnRH-I and its analogs have been demonstrated in a number of malignant human tumors, including cancers of the ovary [6-14]. Data available today suggest that approximately 80% of ovarian cancers express high-affinity GnRH-I receptors [4,5,15]. These findings suggested the presence of a local regulatory system based on GnRH-I. The same situation was found in endometrial, breast and prostate cancer cells [4,5,15,16].
###end p 6
###begin p 7
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 891 892 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1096 1097 1096 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1098 1099 1098 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1100 1102 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1103 1105 1103 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1323 1325 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1326 1328 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1491 1492 1491 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1493 1495 1493 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1867 1868 1867 1868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1869 1871 1869 1871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1872 1874 1872 1874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 221 226 <span type="species:ncbi:9606">human</span>
###xml 440 445 <span type="species:ncbi:9606">human</span>
###xml 496 505 <span type="species:ncbi:10090">nude mice</span>
###xml 1205 1210 <span type="species:ncbi:9606">human</span>
The in vitro proliferation of a variety of human tumor cell lines, including those from ovarian cancers can be inhibited by GnRH-I and its agonistic analogs in a dose- and time-dependent manner [4,9,11,12,17-20]. In most human ovarian cancer cells except for the ovarian cancer cell line EFO-27 GnRH-I antagonists act like agonists indicating that the dichotomy of GnRH-I agonists and antagonists does not exist in tumor cells [5,9]. Using human ovarian cancer cell line OV-1063 xenografted into nude mice, Yano et al. [12] demonstrated a significant inhibition of tumor growth by chronic treatment with the GnRH-I antagonist Cetrorelix but not with the GnRH-I agonist Triptorelin. As both GnRH-I analogs induced a comparable suppression of the pituitary-gonadal axis, the authors speculated that in vivo anti tumor effects of Cetrorelix were exerted directly on GnRH-I receptors in tumors [8]. The findings on direct anti tumor effects of GnRH-I analogs in ovarian and endometrial cancer reported by several other groups are completely or partly in agreement with the results described earlier [4,8,21,22]. In contrast, other investigators failed to detect direct anti tumor effects of GnRH-I analogs in human ovarian and endometrial cancer cell lines or observed them only at extremely high GnRH-I analog concentrations [23-25]. These discrepancies might be due to the fact that probably the majority of the cell lines used by these authors did not express high-affinity GnRH-I receptors [4,26]. Alternatively, differences in culture or experimental conditions as well as in the types of GnRH-I analogs used might be responsible for the observed variance. In the case of prostate cancer, several groups reported direct antiproliferative effects of GnRH-I analogs in vitro and in animal in vivo models, which could be mediated through specific GnRH-I-binding sites [1,27-32].
###end p 7
###begin p 8
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 156 161 <span type="species:ncbi:9606">human</span>
###xml 321 326 <span type="species:ncbi:9606">human</span>
The proliferation of human ovarian cancer cells was significantly increased after treatment with an antiserum to GnRH-I, suggesting that GnRH-I produced by human ovarian cancer cells acts as a negative autocrine regulator of proliferation [33]. In contrast, Arencibia and Schally [34] have recently reported that in ES-2 human ovarian cancer cells GnRH-I agonist Triptorelin at 10 ng/ml stimulated the proliferation in vitro after 48 h, but was inhibitory after 72 h and at concentrations of 1000 ng/ml. GnRH-I antagonist Cetrorelix inhibited growth of ES-2 cell line only at 1000 ng/ml. The incubation of ES-2 ovarian cancer cells in vitro with an GnRH-I antibody inhibited cell proliferation in a time and concentration-dependent manner. These results suggest that GnRH-I may function as an autocrine growth factor in this ovarian cancer cell line [34]. Differences between tumor cell lines e.g. variances in G-protein coupling and signaling might explain these discrepancies.
###end p 8
###begin title 9
Signaling mechanisms mediating the direct anti-tumor effects of GnRH-I
###end title 9
###begin p 10
###xml 446 447 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 573 575 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 748 750 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 751 753 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 925 927 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 928 930 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 938 940 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 984 986 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1169 1171 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1174 1180 1166 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-fos </italic>
###xml 1192 1194 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1228 1230 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1238 1240 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1366 1368 1358 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1369 1371 1361 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1372 1374 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1382 1384 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1441 1443 1433 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1444 1446 1436 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1447 1449 1439 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1450 1452 1442 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1453 1455 1445 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1456 1458 1448 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 226 231 <span type="species:ncbi:9606">human</span>
During the last ten years, the signaling mechanisms mediating the antiproliferative effects of GnRH-I analogs in ovarian, endometrial and breast cancer cells have been elucidated. The signaling mechanism of GnRH-I receptor in human cancers is quite different from that in pituitary gonadotrophs, where GnRH-I receptors couple to G-protein alphaq and activate phospholipase C (PLC), protein kinase C (PKC), and adenylyl cyclase (AC) [reviewed in [4]]. Although we could clearly demonstrate the activation of PLC, PKC, and AC in these tumor cells by pharmacological stimuli [35], the signaling pathways induced by GnRH-I in pituitary gonadotrophs were not activated by GnRH-I agonist Triptorelin in ovarian, endometrial and breast cancer cell lines [35,36]. We found, however, that after binding of its ligand, the GnRH-I receptor in these cancers couples to G-protein alphai and activates a phosphotyrosine phosphatase (PTP) [35-40] (Fig. 1A). This PTP dephosphorylates EGF receptors [36]. As a result, mitogenic signaling induced by EGF binding to its receptor is abrogated leading to a suppression of EGF-induced activation of mitogen-activated protein kinase (MAPK) [35], c-fos expression [41], and EGF-induced proliferation [35] (Fig. 1A). These findings are in accord with reports that GnRH-I analogs reduce expression of growth factor receptors and their mRNA [12,42,43] (Fig. 1B) and/or growth factor induced tyrosine kinase activity [35,37-39,42,44-46]. The reason for the differences of the GnRH-I receptor signaling between pituitary gonadotrophs and tumor cells remains unclear, as we could not find mutations or splice variants in the tumor GnRH-I receptor which might explain this phenomenon.
###end p 10
###begin p 11
###xml 66 69 66 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A) </bold>
###xml 245 248 245 248 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B) </bold>
###xml 325 328 325 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C) </bold>
###xml 567 570 547 550 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D) </bold>
###xml 755 759 735 739 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0/1 </sub>
###xml 808 811 788 791 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E) </bold>
###xml 1267 1268 1243 1244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 853 858 <span type="species:ncbi:9606">human</span>
###xml 880 885 <span type="species:ncbi:9606">human</span>
GnRH-I and GnRH-II signaling in human gynecological cancer cells: A) GnRH-I activates a phosphotyrosine phosphatase (PTP) inhibiting the mitogenic signal transduction of growth factor receptors resulting in downregulation of cell proliferation. B) GnRH-I downregulates epidermal growth factor (EGF) receptor mRNA expression. C) Activated GnRH-I receptor induces nucleus factor kappaB (NFkappaB) activation and nuclear translocation of activated NFkappaB. Activated NFkappaB now couples to kappaB DNA binding sites and induces expression of anti-apoptotic mechanisms. D) GnRH-I activates c-Jun N-terminal kinase (JNK), induces JunD-DNA binding and stimulates activator protein (AP-1) activity, resulting in reduced proliferation as indicated by increased G0/1 phase of cell cycle and decreased DNA synthesis. E) Unknown signal transduction of a putative human GnRH-II receptor. In human gynecological cancer cells GnRH-I analogs mediate antiproliferative actions via inhibition of growth factor-induced mitogenic signal transduction. In addition GnRH-I induces growth factor receptor downregulation. GnRH-I protects the cancer cells from apoptosis via activation of NFkappaB, stimulates AP-1 activity and extends cell cycle. PPTK, receptor protein tyrosine kinase; GRB2, adaptor protein; SOS, guanine nucleotide exchange factor; RAS, small GTPase; RAF, a protein-serine/threonine kinase; MAPK-K, mitogen activated kinase kinase; MAPK, mitogen activated kinase; TCF, transcription factor; IkappaB, inhibitory kappaB; Gq, G-protein alphaq; Gi, G-protein alphai; p50, p65, NFkappaB subunits.
###end p 11
###begin p 12
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 722 724 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 854 856 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 826 831 <span type="species:ncbi:9606">human</span>
Recently, it was speculated that induction of apoptosis might be involved in the antiproliferative activity of GnRH-I and its analogs [47-49]. However, though we have tried to show induction of apoptosis by GnRH-I analogs, we have found it only in one (Ca-Ov-3) of nine (EFO-21, EFO-27, OVCAR-3, AN-3-CA, Ca-Ov-3, SK-OV-3) ovarian cancer cell lines [[50] and unpublished results]. In contrast, we found that GnRH-I agonist Triptorelin reduced apoptosis induced by the cytotoxic agent doxorubicin. Since Triptorelin-induced reduction of Doxorubicin-induced apoptosis was blocked by inhibition of nucleus factor kappa B (NFkappaB) translocation into the nucleus and Triptorelin was shown to induce NFkappaB activation (Fig. 1C), we concluded that GnRH-I has an antiapoptotic effect mediated through NFkappaB activation in these human ovarian cancer cells [50]. This possibility to protect ovarian cancer cells from programmed cell death is a new and important feature in GnRH-I signaling in ovarian tumors apart from the inhibitory interference with the mitogenic pathway.
###end p 12
###begin p 13
###xml 334 336 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 403 405 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 413 415 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 583 585 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 729 731 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 891 893 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
Recently, it became evident that it is not only mitogenic signaling of growth factor receptors that is modulated by GnRH-I in human cancers. In human ovarian and endometrial cancer cells GnRH-I agonist Triptorelin stimulates the activity of activator protein-1 (AP-1) mediated through pertussis toxin-sensitive G-protein alphai (Fig. 1D). In addition, Triptorelin activates JNK, known to activate AP-1 [51] (Fig. 1D). In earlier investigations we have shown that Triptorelin does not activate phospholipase C (PLC) and protein kinase C (PKC) in endometrial and ovarian cancer cells [35]. In addition, it has been demonstrated that Triptorelin inhibits growth factor-induced mitogen activated protein kinase (MAPK, ERK) activity [35]. Thus Triptorelin-induced activation of the JNK/AP-1 pathway in endometrial cancer cells is independent of the known AP-1 activators, PKC or MAPK (ERK) (Fig. 1D).
###end p 13
###begin p 14
###xml 332 334 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 491 497 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-jun </italic>
###xml 588 590 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 713 715 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 791 797 779 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-jun </italic>
###xml 813 819 801 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-jun </italic>
###xml 952 958 940 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-jun </italic>
###xml 1191 1195 1179 1183 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0/1 </sub>
###xml 1249 1251 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 1582 1584 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 441 446 <span type="species:ncbi:9606">human</span>
###xml 485 489 <span type="species:ncbi:10116">rats</span>
In ovarian and endometrial cancer cells GnRH-I analogs mediate antiproliferative actions via inhibition of growth factor-induced mitogenic signal transduction. GnRH-I agonist Triptorelin protects the cancer cells from apoptosis via activation of NFkappaB, and Triptorelin stimulates AP-1 and JNK activity. Recently Yamauchi et al. [52] found that JNK is involved in inhibition of cell proliferation induced by alpha1B-adrenergic receptor in human embryonic kidney cells. In a study in rats, c-jun mRNA depression and endometrial epithelial cell proliferation were suggested to be linked [53]. In UT-OC-3 ovarian cancer cells cytokines have inhibitory effects on cell proliferation and activate AP-1 and NFkappaB [54]. Since the antiproliferative GnRH-I agonist Triptorelin activates the JNK/c-jun pathway and JNK/c-jun was found to be involved in downregulation of cell proliferation in different systems, it seems reasonable to speculate that the JNK/c-jun pathway is involved in the antiproliferative actions of the GnRH agonist Triptorelin. In addition, we have shown that GnRH-I agonist Triptorelin induces JunD-DNA binding, resulting in reduced proliferation as indicated by increased G0/1 phase of cell cycle and decreased DNA synthesis (Fig. 1D). Since GnRH-I activates NFkappaB and protects ovarian cancer cells from Doxorubicin-induced apoptosis and JunD is shown to decrease cell cycle and cell proliferation, we propose that JunD activated by GnRH-I acts as a modulator of cell proliferation and cooperates with the anti-apoptotic and anti-mitogenic functions of GnRH-I [55].
###end p 14
###begin title 15
GnRH-II and its receptor
###end title 15
###begin p 16
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1086 1088 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 306 311 <span type="species:ncbi:9606">human</span>
###xml 754 767 <span type="species:ncbi:9544">rhesus monkey</span>
###xml 820 833 <span type="species:ncbi:9544">rhesus monkey</span>
###xml 992 1005 <span type="species:ncbi:9544">rhesus monkey</span>
In non-mammalian vertebrates it became evident that three structural variants of GnRH were present in individual species [56,57]. A similar situation seems to exist in mammals. One of these GnRH variants is GnRH-II, which is totally conserved in structure in the evolution from fish to mammals [58,59]. In human granulosa-luteal cells expression of GnRH-II was found [60]. In these cells GnRH-I agonists exerted a biphasic effect on GnRH-I receptor density, while GnRH-II agonists induced a downregulation of GnRH-I receptor expression and of GnRH-II itself [60]. Recently Millar et al. cloned a type II GnRH receptor from the marmoset monkey which is highly selective for GnRH-II [61]. At the same time Neill et al. cloned the GnRH-II receptor from the rhesus monkey [62]. Only 41% (marmoset GnRH-II receptor) and 39% (rhesus monkey GnRH-II receptor) identities with the GnRH-I receptor have been reported [61,62]. In contrast to the GnRH-I receptor the GnRH-II receptor in the marmoset and rhesus monkey has a C-terminal, cytoplasmatic tail resulting in a more rapid internalization [61,62].
###end p 16
###begin p 17
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 925 926 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1172 1193 1172 1193 <bold xmlns:xlink="http://www.w3.org/1999/xlink">[unpublished results]</bold>
###xml 1318 1339 1318 1339 <bold xmlns:xlink="http://www.w3.org/1999/xlink">[unpublished results]</bold>
###xml 1709 1711 1709 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 983 988 <span type="species:ncbi:9606">human</span>
###xml 1640 1645 <span type="species:ncbi:9606">human</span>
###xml 1730 1735 <span type="species:ncbi:9606">human</span>
Using RT-PCR and Southern blot analysis we could recently show that human ovarian and endometrial cancer cells express a putative second GnRH receptor specific for GnRH-II [63] (Fig. 1E). The proliferation of these cell lines was reduced in a dose- and time-dependent manner by native GnRH-II. These effects were significantly higher than the antiproliferative effects of equimolar doses of GnRH-I agonist Triptorelin [63]. In the GnRH-II receptor mRNA positive but GnRH-I receptor negative ovarian cancer cell line SK-OV-3 native GnRH-II but not GnRH-I agonist Triptorelin had antiproliferative effects [63]. In previous studies we have demonstrated that in ovarian cancer cell lines except for the EFO-27 cell line GnRH-I antagonist Cetrorelix has comparable antiproliferative effects as GnRH-I agonists indicating that the dichotomy of GnRH-I agonists and antagonists might not apply to the GnRH-I system in cancer cells [9] After GnRH-I receptor knock down in EFO-21 and OVCAR-3 human ovarian cancer cell lines the antiproliferative effects of GnRH-I agonist Triptorelin were abrogated while the effects of GnRH-I antagonist Cetrorelix and GnRH-II were still existing [unpublished results]. In addition, in the ovarian cancer cell line EFO-27 GnRH-I receptor but not putative GnRH-II receptor expression was found [unpublished results]. These data suggest that in ovarian and endometrial cancer cells the antiproliferative effects of GnRH-I antagonist Cetrorelix and GnRH-II are not mediated through the GnRH-I receptor. It is possible that these antiproliferative effects are mediated through a putative GnRH-II receptor. However, the human GnRH-II receptor is expressed as a variety of splice variants [64] and a functional human GnRH-II receptor transcript has not been found until now. Further investigations are required to determine whether these GnRH-II receptor splice variants translate to functional proteins.
###end p 17
###begin p 18
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 530 532 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 623 625 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 769 771 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1029 1031 1021 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 156 161 <span type="species:ncbi:9606">human</span>
###xml 303 308 <span type="species:ncbi:9606">human</span>
###xml 982 987 <span type="species:ncbi:9606">human</span>
Gonadotropin biosynthesis and secretion by GnRH-I can be mediated by activation of MAP kinases. Therefore, Millar et al. [61] assessed the capacity of both human GnRH-I receptor and marmoset GnRH-II receptor to activate the MAP kinases ERK2, JNK, and p38alpha in COS-7 cells transfected with either the human GnRH-I receptor or the marmoset GnRH-II receptor. At the GnRH-I receptor, GnRH-I was considerably more potent than GnRH-II in activating ERK2 whereas at the GnRH-II receptor, GnRH-II was markedly more potent than GnRH-I [61]. Neither GnRH-I receptor nor GnRH-II receptor stimulation resulted in activation of JNK [61]. Activation of p38alpha was detected on stimulation of GnRH-II receptor with GnRH-II but not with stimulation of GnRH-I receptor with GnRH-I [61]. These data suggest that there are distinct differences in the signal transduction by the two GnRH receptors. However, the signal transduction mechanisms mediating the antiproliferative activity of GnRH-II in human ovarian cancer cells are not known (Fig. 1E).
###end p 18
###begin p 19
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 197 202 <span type="species:ncbi:9606">human</span>
As the antiproliferative activity of native GnRH-II is significantly superior to that of the GnRH-I superagonists, superactive agonists of GnRH-II might become efficacious drugs for the therapy of human cancers. However, the more widely distributed expression pattern of GnRH-II receptor [61] could limit the effectiveness of GnRH-II agonists.
###end p 19
###begin title 20
Acknowledgements
###end title 20
###begin p 21
Our work was supported by the Deutsche Forschungsgemeinschaft (SFB 215-B10 and GR 1895/2-1), the PE Kempkes Foundation, Marburg, Germany, the Bundesministerium fur Bildung und Forschung, the German-Israeli Foundation for Scientific Research and Development (I-684-176.2/2000), Ferring Pharmaceuticals, Copenhagen, Denmark, Asta Medica AG, Frankfurt, Germany.
###end p 21
###begin article-title 22
Hypothalamic hormones from neuroendocrinology to cancer therapy
###end article-title 22
###begin article-title 23
Expression and signal transduction pathways of gonadotropin-releasing hormone receptors
###end article-title 23
###begin article-title 24
Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone
###end article-title 24
###begin article-title 25
###xml 30 35 <span type="species:ncbi:9606">human</span>
Biology of the GnRH system in human gynecological cancers
###end article-title 25
###begin article-title 26
Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells
###end article-title 26
###begin article-title 27
###xml 48 53 <span type="species:ncbi:9606">human</span>
Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata
###end article-title 27
###begin article-title 28
###xml 75 80 <span type="species:ncbi:9606">human</span>
Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata
###end article-title 28
###begin article-title 29
Lupron retards proliferation of ovarian tumor cells cultured in serum-free medium
###end article-title 29
###begin article-title 30
###xml 80 85 <span type="species:ncbi:9606">human</span>
High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
###end article-title 30
###begin article-title 31
###xml 81 86 <span type="species:ncbi:9606">human</span>
Presence of gonadotropin-releasing hormone and his messenger ribunucleic acid in human ovarian epithelial carcinoma
###end article-title 31
###begin article-title 32
###xml 14 19 <span type="species:ncbi:9606">human</span>
Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone
###end article-title 32
###begin article-title 33
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 78 87 <span type="species:ncbi:10090">nude mice</span>
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75
###end article-title 33
###begin article-title 34
###xml 27 32 <span type="species:ncbi:9606">human</span>
The nucleotide sequence of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary
###end article-title 34
###begin article-title 35
###xml 102 107 <span type="species:ncbi:9606">human</span>
Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma
###end article-title 35
###begin article-title 36
###xml 69 74 <span type="species:ncbi:9606">human</span>
Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation and correlation with direct antiproliferative activity of LHRH analogues
###end article-title 36
###begin article-title 37
###xml 86 91 <span type="species:ncbi:9606">human</span>
Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop
###end article-title 37
###begin article-title 38
The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancers
###end article-title 38
###begin article-title 39
###xml 111 116 <span type="species:ncbi:9606">human</span>
High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines
###end article-title 39
###begin article-title 40
###xml 10 15 <span type="species:ncbi:9606">human</span>
Growth of human breast cancer cells inhibited by luteinizing hormone-releasing hormone agonist
###end article-title 40
###begin article-title 41
###xml 100 105 <span type="species:ncbi:9606">human</span>
Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line
###end article-title 41
###begin article-title 42
###xml 28 33 <span type="species:ncbi:9606">human</span>
Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis
###end article-title 42
###begin article-title 43
###xml 122 127 <span type="species:ncbi:9606">human</span>
Effect of gonadotropin releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor-positive human cancer cell lines
###end article-title 43
###begin article-title 44
Effects of GnRH analogs on six ovarian cancer cell lines in culture
###end article-title 44
###begin article-title 45
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 48 57 <span type="species:ncbi:10090">nude mice</span>
Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75)
###end article-title 45
###begin article-title 46
The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer and its relevance as an autocrine growth factor
###end article-title 46
###begin article-title 47
Treatment of ovarian cancer with LHRH antagonists
###end article-title 47
###begin article-title 48
###xml 21 26 <span type="species:ncbi:9606">human</span>
Growth inhibition of human prostatic cancer cells by an agonist of gonadotropin-releasing hormone
###end article-title 48
###begin article-title 49
###xml 74 79 <span type="species:ncbi:9606">human</span>
Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth
###end article-title 49
###begin article-title 50
###xml 170 179 <span type="species:ncbi:10090">nude mice</span>
Luteinizing hormone releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
###end article-title 50
###begin article-title 51
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
###end article-title 51
###begin article-title 52
###xml 42 47 <span type="species:ncbi:9606">human</span>
Effects of LHRH agonists on the growth of human prostatic tumor cells: "in vitro" and "in vivo" studies
###end article-title 52
###begin article-title 53
The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumor receptors
###end article-title 53
###begin article-title 54
###xml 109 114 <span type="species:ncbi:9606">human</span>
Luteinizing hormone-releasing hormone (LHRH) might act as a negative autocrine regulator of proliferation of human ovarian cancer
###end article-title 54
###begin article-title 55
Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line
###end article-title 55
###begin article-title 56
###xml 143 148 <span type="species:ncbi:9606">human</span>
Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines
###end article-title 56
###begin article-title 57
###xml 39 44 <span type="species:ncbi:9606">human</span>
Antiproliferative signaling of LHRH in human endometrial and ovarian cancer cells through G-protein alphai-mediated activation of phosphotyrosine phosphatase
###end article-title 57
###begin article-title 58
Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation of tyrosine residues of specific substrates in various tumors
###end article-title 58
###begin article-title 59
Phosphotyrosine phosphatase activity in membranes from endometrial carcinoma
###end article-title 59
###begin article-title 60
Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane
###end article-title 60
###begin article-title 61
###xml 69 74 <span type="species:ncbi:9606">human</span>
Coupling of gonadotropin releasing hormone receptor to Gi protein in human reproductive tract tumors
###end article-title 61
###begin article-title 62
###xml 131 136 <span type="species:ncbi:9606">Human</span>
Luteinizing Hormone-releasing Hormone (LHRH) Agonist Triptorelin and Antagonist Cetrorelix inhibit EGF-induced c-fos Expression in Human Gynecological Cancers
###end article-title 62
###begin article-title 63
###xml 116 121 <span type="species:ncbi:9606">human</span>
Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145
###end article-title 63
###begin article-title 64
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 193 202 <span type="species:ncbi:10090">nude mice</span>
Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice
###end article-title 64
###begin article-title 65
###xml 124 129 <span type="species:ncbi:9606">human</span>
Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell lines
###end article-title 65
###begin article-title 66
Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous receptor-stimulated tyrosine phosphorylation
###end article-title 66
###begin article-title 67
Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin like growth factors
###end article-title 67
###begin article-title 68
Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors
###end article-title 68
###begin article-title 69
Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulate Fas ligand expression in reproductive tumors: possible mechanism for hormonal control of apoptotic cell death
###end article-title 69
###begin article-title 70
Fas and Fas-ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells
###end article-title 70
###begin article-title 71
Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells
###end article-title 71
###begin article-title 72
###xml 123 128 <span type="species:ncbi:9606">human</span>
Protein kinase C (PKC)-independent stimulation of activator protein-1 (AP-1) and c-Jun N-terminal kinase (JNK) activity in human endometrial cancer cells by luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin
###end article-title 72
###begin article-title 73
Involvement of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase in alpha1B-adrenergic receptor/Galphaq-induced inhibition of cell proliferation
###end article-title 73
###begin article-title 74
###xml 54 57 <span type="species:ncbi:10116">rat</span>
Differentially regulated immediate early genes in the rat uterus
###end article-title 74
###begin article-title 75
Regulation of UT-OC-3 ovarian carcinoma cells by cytokines: inhibitory effects on cell proliferation and activation of transcription factors AP-1 and NF-kappaB
###end article-title 75
###begin article-title 76
###xml 89 94 <span type="species:ncbi:9606">human</span>
Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells
###end article-title 76
###begin article-title 77
###xml 63 70 <span type="species:ncbi:9031">chicken</span>
Identification of the second gonadotropin-releasing hormone in chicken hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species
###end article-title 77
###begin article-title 78
Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain
###end article-title 78
###begin article-title 79
###xml 50 56 <span type="species:ncbi:9606">humans</span>
Second gene for gonadotropin-releasing hormone in humans
###end article-title 79
###begin article-title 80
Regional expression of mRNA encoding a second form of gonadotropin-releasing hormone in the macaque brain
###end article-title 80
###begin article-title 81
###xml 101 106 <span type="species:ncbi:9606">human</span>
Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells
###end article-title 81
###begin article-title 82
A novel mammalian receptor for the evolutionarily conserved type II GnRH
###end article-title 82
###begin article-title 83
A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates
###end article-title 83
###begin article-title 84
###xml 70 75 <span type="species:ncbi:9606">human</span>
Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation
###end article-title 84
###begin article-title 85
###xml 27 32 <span type="species:ncbi:9606">human</span>
A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12
###end article-title 85

